Cargando…
Pathogenic roles of IL-6 and IL-6 blocking therapy on rheumatoid arthritis
Autores principales: | Yoshizaki, K, Nishimoto, N, Miyasaka, N, Yamamoto, K, Kawai, S, Takeuchi, T, Kishimoto, T |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833923/ http://dx.doi.org/10.1186/ar933 |
Ejemplares similares
-
Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
por: Nishimoto, N, et al.
Publicado: (2009) -
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
por: Nishimoto, Norihiro, et al.
Publicado: (2008) -
IL-15 and its role in rheumatoid arthritis
por: Kurowska-Stolarska, M, et al.
Publicado: (2003) -
Circulating levels of IL-7 in rheumatoid arthritis
por: Churchman, S, et al.
Publicado: (2007) -
AJAK inhibitor, tofacitinibreduces IL-6 and matrix metalloproteinase-3 productionin rheumatoid arthritis with suppressed cartilage destruction
por: Yamaoka, Kunihiro, et al.
Publicado: (2012)